Morphine extended-release/naltrexone

Drug Profile

Morphine extended-release/naltrexone

Alternative Names: ALO-01; Embeda; KADIAN NT; Morphine ER/naltrexone; Naltrexone/morphine ER

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alpharma
  • Developer Pfizer
  • Class Morphinans; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Pain

Most Recent Events

  • 17 Oct 2014 The US FDA approves sNDA for Pain
  • 29 Jul 2014 The US FDA extends PDUFA date to October 2014 for sNDA review for Pain (PO)
  • 29 Jul 2014 The US FDA sets PDUFA date of July 2014 for sNDA review for Pain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top